Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety of biological active dose of a new experimental
drug, IL-7, in combination with standard bi-therapy in Asiatic patients with Hepatitis C
chronic infection identified as non responders to the standard bi-therapy alone.